Evidence map›Paper›PMID 41737221›Full record

ArticleFrontiers in immunology2026

Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans.

Emna Hannachi, Amélia Trecco, Victoria Daventure, Sandrine Delignat, Perrine Bonilla, Maxime Lecerf, Olivier Thaunat, Jordan D Dimitrov, Claire Deligne, Sébastien Lacroix-Desmazes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emna HannachiInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Amélia TreccoInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Victoria DaventureInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Sandrine DelignatInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Perrine BonillaInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Maxime LecerfInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Olivier ThaunatCIRI, Centre International de Recherche en Immunologie-infectiologie, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Jordan D DimitrovInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Claire DeligneInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.
Sébastien Lacroix-DesmazesInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Centre National de la Recherche Scientifique (CNRS), Sorbonne Université, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The IgG-degrading enzyme IdeS (imlifidase) is a cysteine protease produced by Methods: In this study, we developed semi-quantitative enzyme-linked immunosorbent assays, synthesized a specific IdeS substrate, and validated a quantitative neutralization assay to detect and quantify anti-IdeS IgG, IgA, and IdeS neutralizing antibodies in healthy human plasma and serum samples. Results: We demonstrate the presence of anti-IdeS IgG capable of neutralizing IdeS enzymatic activity in therapeutic preparations of pooled normal human IgG (IVIg). Anti-IdeS IgG and IgA antibodies were detected in the plasma and serum of over 85% of 136 healthy individuals. However, clinically significant levels of IdeS-neutralizing activity were found in only ~1% of the individuals tested. IdeS-neutralizing activity was mediated exclusively by IgG, not IgA, and did not systematically correlate with levels of anti-IdeS IgG. Conclusions: Anti-IdeS IgG and IgA are highly prevalent in the normal population. This may relate to repeated infection by

Indexed as

Antibodies, BacterialAntibodies, NeutralizingBacterial ProteinsStreptococcus pyogenesEnzyme-Linked Immunosorbent AssayFemaleHealthy VolunteersHumansImmunoglobulin AImmunoglobulin GAntibodies, BacterialAntibodies, NeutralizingBacterial ProteinsImmunoglobulin AImmunoglobulin GMac-1-like protein, Streptococcusanti-IdeS antibodiesIdeSImlifidaseneutralizing antibodiespre-existing immunitysynthetic FRET substrate

Identifiers

PMID41737221
PMCPMC12926173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.